ZYME - Zymeworks Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
16.51
+1.18 (+7.70%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close15.33
Open15.41
Bid16.55 x 1000
Ask16.61 x 1200
Day's Range15.33 - 16.88
52 Week Range6.87 - 29.00
Volume177,111
Avg. Volume105,451
Market Cap527.49M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy.

  • Barrons.com6 days ago

    Eli Lilly Is Selling More Shares of This Biopharma Firm

    INSIDE SCOOP (LLY) (LLY) continues to trim its stake in (ZYME) (ZYME). After selling $508,000 of Zymeworks shares in August, Lilly this week sold another $681,130 of shares of the Vancouver-based biopharmaceutical firm.

  • Barrons.com15 days ago

    Eli Lilly Has Trimmed Its Stake in Biopharma Firm Zymeworks

    Eli Lilly (LLY) sold half-a-million dollars in shares of Zymeworks (ZYME) over the month of August. From Aug. 2 through 31, Lilly sold 36,931 shares of the Vancouver-based biopharmaceutical firm for a total of $507,759, or $13.75 per share on average — 75 cents above Zymeworks’ May 2017 initial-public-offering price. Lilly now owns 3.92 million Zymeworks shares, a stake of about 14.6% based on an average 26.9 million shares outstanding at June 30.

  • Business Wire16 days ago

    Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an IND application for a bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform. Previously, Zymeworks announced Lilly’s nomination of two bispecific immuno-oncology drug candidates for late-stage preclinical development.

  • Business Wire22 days ago

    Zymeworks to Present at Wells Fargo Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

  • Business Wire2 months ago

    Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

  • Business Wire2 months ago

    Zymeworks Reports Financial Results for the Second Quarter of 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2018.

  • Business Wire3 months ago

    Zymeworks Closes Previously Announced Public Offering

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.

  • Business Wire3 months ago

    Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

    Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018 .

  • Business Wire3 months ago

    Zymeworks Announces Pricing of Public Offering

    Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today the pricing of its previously- announced underwritten public offering (the “Offering”) of 5,400,000 common shares at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$85.1 million, before deducting the underwriting discounts and commissions and estimated Offering expenses. In addition, the Company has also granted the underwriters of the Offering a 30-day over-allotment option to purchase up to an additional 810,000 common shares on the same terms and conditions.

  • Business Wire3 months ago

    Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated May 24, 2018 (the “Base Prospectus”) in connection with an offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Canada. The Supplement was also filed with the U.S. Securities and Exchange Commission (the “SEC”) as part of a registration statement on Form F-10, as amended (the “Registration Statement”), in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

  • Business Wire4 months ago

    Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center. Data from the ongoing multi-center Phase 1 study showed single agent ZW25 induced anti-tumor activity and was well tolerated in heavily pretreated patients across a range of HER2-expressing cancers.

  • Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
    Business Wire4 months ago

    Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement.

  • Business Wire4 months ago

    Zymeworks to Present at the UBS Global Healthcare Conference 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming UBS Global Healthcare Conference taking place May 21-23, 2018 in New York, NY, USA.

  • Business Wire5 months ago

    Zymeworks Reports 2018 First Quarter Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the quarter ended March 31, 2018.

  • Business Wire5 months ago

    Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co.

  • Business Wire5 months ago

    Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that the abstract highlighting new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1 through 5, 2018. The oral presentation, entitled “Single Agent Activity of ZW25, a HER2 Targeted Bispecific Antibody, in Heavily Pretreated HER2 Expressing Cancers,” is scheduled for Friday June 1, 2018 at 2:45 pm CT during the session on Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics in room S406.

  • Business Wire5 months ago

    Zymeworks and Celgene Expand Bispecific Antibody Collaboration

    Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform. “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and we are delighted to expand and continue our relationship with them,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO.

  • Business Wire5 months ago

    Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate and its ZymeLink ADC platform.

  • Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?
    Simply Wall St.6 months ago

    Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?

    When Zymeworks Inc’s (TSX:ZYME) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...

  • Business Wire6 months ago

    Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that ZW49 is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics.

  • Business Wire6 months ago

    Zymeworks Reports 2017 Year-End Financial Results

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2017.

  • Business Wire6 months ago

    Zymeworks to Present at Barclays 2018 Global Healthcare Conference

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 13-15, 2018 in Miami Beach, Florida.

  • Business Wire7 months ago

    Zymeworks Opening Clinical Sites in Canada

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the addition of new clinical sites in Canada and the United States for its ongoing adaptive Phase 1 study of the company’s lead clinical candidate, ZW25.

  • Business Wire8 months ago

    Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities

    Zymeworks Inc. , a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today provided key accomplishments from the past year and announced priorities for 2018.